Maillard Michel H, Bega Hristina, Uhlig Holm H, Barnich Nicolas, Grandjean Teddy, Chamaillard Mathias, Michetti Pierre, Velin Dominique
*Service of Gastroenterology and Hepatology, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland; †Translational Gastroenterology Unit, Division of Experimental Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom; ‡M2iSH, UMR1071 Inserm, Université d'Auvergne, USC-INRA 2018, Clermont-Ferrand, France; §Institut Universitaire de Technologie en Génie Biologique, Aubière, France; ‖Univ Lille Nord de France, Lille, France; ¶Institut Pasteur de Lille, Center for Infection and Immunity of Lille, Lille, France; **Centre National de la Recherche Scientifique, Unité Mixte de Recherche 8204, Lille, France; ††Institut National de la Santé et de la Recherche Médicale, U1019, Team 7, Equipe FRM, Lille, France; and ‡‡La Source-Beaulieu, Lausanne, Switzerland.
Inflamm Bowel Dis. 2014 Apr;20(4):660-70. doi: 10.1097/MIB.0000000000000006.
The intestinal epithelium accommodates with a myriad of commensals to maintain immunological homeostasis, but the underlying mechanisms regulating epithelial responsiveness to flora-derived signals remain poorly understood. Herein, we sought to determine the role of the Toll/interleukin (IL)-1 receptor regulator Toll-interacting protein (Tollip) in intestinal homeostasis.
Colitis susceptibility was determined after oral dextran sulfate sodium (DSS) administration or by breeding Tollip on an IL-10 background. The intestinal flora was depleted with 4 antibiotics before DSS exposure to assess its contribution in colitis onset. Bone marrow chimeras were generated to identify the cellular compartment, whereby Tollip may negatively regulate intestinal inflammation in response to DSS. Tollip-dependent epithelial barrier functions were studied in vitro by using Tollip-knockdown in Caco-2 cells and in vivo by immunohistochemistry and fluorescein isothiocyanate-labeled dextran gavage.
Genetic ablation of Tollip did not lead to spontaneous intestinal inflammatory disorders. However, Tollip deficiency aggravated spontaneous disease onset in IL-10 mice and increased susceptibility to DSS colitis. Increased colitis severity in Tollip-deficient mice was not improved by bacterial flora depletion using broad-spectrum antibiotics. In addition, DSS exposure of bone marrow chimeric mice revealed a protective role for Tollip in nonhematopoietic cells. Knockdown of Tollip in epithelial cells led to exaggerated NFκ-B activity and proinflammatory cytokine secretion. Finally, DSS-treated Tollip mice showed enhanced intestinal permeability and increased epithelial apoptosis when compared with wild-type controls, a finding that coincided with tight junction alterations on injury.
Overall, our data show an essential role for Tollip on colitis susceptibility in mice.
肠道上皮细胞与众多共生菌相互适应以维持免疫稳态,但调节上皮细胞对菌群衍生信号反应性的潜在机制仍知之甚少。在此,我们试图确定Toll/白细胞介素(IL)-1受体调节因子Toll相互作用蛋白(Tollip)在肠道稳态中的作用。
通过口服葡聚糖硫酸钠(DSS)或在IL-10背景下培育Tollip来确定结肠炎易感性。在DSS暴露前用4种抗生素清除肠道菌群,以评估其在结肠炎发病中的作用。构建骨髓嵌合体以确定Tollip可能通过负调节肠道炎症来应对DSS的细胞区室。通过在Caco-2细胞中敲低Tollip在体外研究Tollip依赖性上皮屏障功能,并通过免疫组织化学和异硫氰酸荧光素标记的葡聚糖灌胃在体内进行研究。
Tollip的基因敲除并未导致自发性肠道炎症性疾病。然而,Tollip缺陷加剧了IL-10小鼠的自发性疾病发作,并增加了对DSS结肠炎的易感性。使用广谱抗生素清除细菌菌群并不能改善Tollip缺陷小鼠结肠炎的严重程度。此外,对骨髓嵌合小鼠进行DSS暴露揭示了Tollip在非造血细胞中的保护作用。上皮细胞中Tollip的敲低导致NFκ-B活性和促炎细胞因子分泌增加。最后,与野生型对照相比,DSS处理的Tollip小鼠显示肠道通透性增强和上皮细胞凋亡增加,这一发现与损伤时紧密连接的改变一致。
总体而言,我们的数据表明Tollip在小鼠结肠炎易感性中起重要作用。